[go: up one dir, main page]

WO1994012173A1 - Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation - Google Patents

Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation Download PDF

Info

Publication number
WO1994012173A1
WO1994012173A1 PCT/GB1992/002222 GB9202222W WO9412173A1 WO 1994012173 A1 WO1994012173 A1 WO 1994012173A1 GB 9202222 W GB9202222 W GB 9202222W WO 9412173 A1 WO9412173 A1 WO 9412173A1
Authority
WO
WIPO (PCT)
Prior art keywords
trans
formula
dihydro
dimethyl
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1992/002222
Other languages
English (en)
Inventor
John Morris Evans
Mervyn Thompson
Neil Upton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to SK709-95A priority Critical patent/SK281507B6/sk
Priority to PL92309219A priority patent/PL173268B1/pl
Priority to CZ951390A priority patent/CZ282172B6/cs
Priority to FI952609A priority patent/FI952609L/fi
Priority to BR9207178A priority patent/BR9207178A/pt
Priority to HU9501563A priority patent/HUT72589A/hu
Priority to PCT/GB1992/002222 priority patent/WO1994012173A1/fr
Publication of WO1994012173A1 publication Critical patent/WO1994012173A1/fr
Priority to NO19952119A priority patent/NO315733B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4

Definitions

  • Benzopyron analogues for the treatment of anxiety, mania, depression or withdrawal symptoms are Benzopyron analogues for the treatment of anxiety, mania, depression or withdrawal symptoms.
  • This invention relates to a novel method of treatment and to novel
  • European Published Patent Application No. 0126311 discloses substituted benzopyran compounds having blood pressure lowering activity, including 6-acetyl-trans-4-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1- benzopyran-3-ol.
  • EP-A-0 376 524, EP-A-0 205 292, EP-A-0 250 077, EP-A-0 093 535, EP-A-0 150 202, EP-A-0 076 075 and WO/89/05808 (Beecham Group pic) describe certain benzopyran derivatives which possess anti-hypertensive activity.
  • EP-A-0 430 621 and EP-A-0 385 584 (Beecham Group pic) describe the resolution of certain intermediates useful in the preparation of the
  • EP-A-0 194 885 (E. Lilly) describes certain amino substituted benzopyran derivatives possessing anti-convulsant activity.
  • the present invention provides a method of treatment and/or prophylaxis of anxiety and/or mania, and/or depression and/or the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, and/or disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy, comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I) or pharmaceutically acceptable salt thereof:
  • Y is N and R 2 is hydrogen, or Y is C-R 1 where: either one of R 1 and R 2 is hydrogen and the other is selected from the class of hydrogen, C 3-8 cycloalkyl, C 1-6 alkyl optionally interupted by oxygen or substituted by hydroxy, C 1-6 alkoxy or substituted
  • alkylcarbonyloxy C 1-6 alkoxy, nitro, cyano, halo, trifluoromethyl, CF 3 S, or a group CF 3 -A-, where A is -CF 2 -, -CO-, -CH 2 - or CH(OH),
  • C 1-6 alkylsulphinyl C 1-6 alkylsulphonyl, C 1-6 alkoxysulphinyl, C 1-6 alkoxysulphonyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulphinyl, heteroarylsulphinyl, arylsulphonyl, heteroarylsulphonyl in which any aromatic moiety is optionally
  • alkylsulphonylamino C 1-6 alkoxysulphinylamino or C 1-6
  • alkoxysulphonylamino or ethylenyl terminally substituted by C 1-6 alkylcarbonyl, nitro or cyano, or -C(C 1-6 alkyl)NOH or -C(C 1-6
  • R 1 and R 2 is nitro, cyano or C 1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C 1-6 alkyl or by C 2-7 alkanoyl
  • one of R 3 and R 4 is hydrogen or C 1-4 alkyl and the other is C 1-4 alkyl or R 3 and R 4 together are C 2-5 polymethylene
  • R 5 is C 1-6 alkylcarbonyloxy, benzoyloxy, ONO 2 , benzyloxy, phenyloxy or C 1-6 alkoxy and R 6 and R 9 are hydrogen or R 5 is hydroxy and R 6 is hydrogen or C 1-2 alkyl and R 9 is hydrogen;
  • R 7 is fluorophenyl
  • R 8 is hydrogen or C 1-6 alkyl
  • the R 8 -N-CO-R 7 group being trans to the R 5 group
  • X is oxygen or NR 10 where R 10 is hydrogen or C 1-6 alkyl.
  • Compounds of formula (I) include those in which Y is C-R 1 , where; either one of R 1 and R 2 is hydrogen and the other is selected from the class of hydrogen, C 1-6 alkylcarbonyl, C 1-6 alkoxy carbonyl, C 1-6 alkylcarbonyloxy, C 1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, trifluoromethoxy, C 1-6 alkylsulphinyl, C 1-6
  • alkylsulphonyl C 1-6 alkoxysulphinyl, C 1-6 alkoxysulphonyl, C 1-6 alkylcarbonylamino, C 1-6 alkoxycarbonylamino, C 1-6 alkyl-thiocarbonyl, C 1-6 alkoxy-thiocarbonyl, C 1-6 alkyl-thiocarbonyloxy, 1-mercapto C 2-7 alkyl, formyl, or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C 1-6 alkyl groups, or C 1-6 alkylsulphinylamino, C 1-6 alkylsulphonylamino,C 1-6 alkoxysulphinylamino or C 1-6 alkoxysulphonylamino, or ethylenyl terminally substituted by C 1-6 alkylcarbonyl, nitro or cyano, or -C(C 1-6 alkyl)NOH
  • All C 1-6 alkyl or alkyl containing groups in formula (I) are preferably selected from methyl, ethyl, n- and iso-propvl. n -, iso-, sec- and tert-butyl.
  • Suitable C 3-8 cycloalkyl groups include cyclopropyl, cyclobutyl,
  • Aryl includes but is not limited to phenyl and naphthyl.
  • Heteroaryl includes a 5- or 6- membered monocyclic or 9- or 10- membered bicyclic of which 5- or 6- membered monocyclic heteroaryl is preferred.
  • 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heteroaryl preferably contains one, two or three heteroatoms which are selected from the class of oxygen, nitrogen and sulphur and which, in the case of there being more than one heteroatom, are the same or different.
  • Examples of 5- or 6-membered monocyclic heteroaryl containing one, two or three heteroatoms which are selected from the class of oxygen, nitrogen and sulphur include furyl, thienyl, pyrryl, oxazolyl, thiazolyl, imidazolyl and thiadiazolyl, and pyridyl, pyridazyl, pyriroidyl, pyrazolyl and triazolyl.
  • Preferred examples of such groups include furanyl, thienyl, pyrryl and pyridyl, in particular 2- and 3-furyl, 2- and 3-pyrryl, 2- and 3-thienyl, and 2-, 3- and 4-pyridyl.
  • Examples of 9- or 10-membered bicyclic heteroaryl containing one, two or three heteroatoms which are selected from the class of oxygen, nitrogen and sulphur include
  • Preferred examples of such groups include 2- and 3-benzofuryl, 2- and 3-benzothienyl, and 2- and 3-indolyl, and 2- and 3-quinolyl.
  • R 2 is hydrogen
  • R 1 substituents examples include cyano, methoxy,
  • R 1 is cyano, acetyl or ethyl.
  • R 3 and R 4 are both methyl.
  • R 5 is hydroxy and R 6 and R 9 are hydrogen or R 5 is hydroxy, R 6 is C 1-2 alkyl and R 9 is hydrogen, more preferably R 5 is hydroxy and R 6 and R 9 are hydrogen.
  • fluorophenyl relating to R 7 encompasses phenyl which has 1,2,3,4 or 5 fluoro groups attached to the phenyl ring. Preferably there are 1 or 2 fluoro groups attached to the phenyl ring and most preferably there is 1 fluoro group attached to the ring.
  • the fluoro group or groups may be in any position around the phenyl ring, preferably in the case of mono fluorophenyl the fluoro is in the 3 or 4 position.
  • the fluoro substituents are at positions 2,4 or 3,4.
  • R 8 is hydrogen or C 1-4 alkyl, more preferably R 8 is hydrogen, methyl or ethyl.
  • X is oxygen
  • the compounds of formula (I) may have chiral carbon atoms at positions 2, 3 and 4 and therefore may exist as enantiomers.
  • the present invention extends to each enantiomer and to mixtures thereof including racemates.
  • the compounds of formula (I) exist as 4S, 3R enantiomers.
  • R 1 substituents also have chiral centres and therefore may exist as enantiomers.
  • the present invention extends to each enantiomer and to mixtures thereof including racemates
  • novel compounds of formula (I) also form an aspect of the present invention, (herein referred to as compounds of formula (I')): trans-6-Cyano-3,4-dihydro-2,2-dimethyl-4-(4-fluorobenzoylamino)2H-1-benzopyran-3-ol, (Example 5), trans-6-Chloro-3,4-dihydro-2,2-dimethyl-4-(4-fluorobenzoylamino)2H-1-benzopyran-3-ol, (Example 6), trans-6- Trifluoromethyl-4-(4-fluorobenzoylamino)-3,4-dihydro-2,2- dimethyl-2H-1-benzopyran-3-ol, (Example 7), trans-6-Cyano-4-(4-fluorobenzoylmethylamino)-3,4-dihydro- 2,2-dimethyl- 2H-1-benzopyran-3-ol, (Example 8), trans-6-
  • the administration to the mammal may be by way of oral or parenteral administration.
  • An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal.
  • a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 100 mg such as 2, 5, 10, 20, 30, 40, 50 and 100 mg of the active compound.
  • Unit doses will normally be
  • the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 50 to 500 mg, that is in the range of approximately 0.01 to 50 mg/kg/day, more usually 0.1 to 50 mg/kg/day, for example 1 to 50 mg/kg/day.
  • the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, rectal, topical or parenteral (especially intravenous) composition.
  • compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
  • Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch,
  • polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia
  • non-aqueous vehicles which may include edible oils
  • almond oil fractionated
  • Oral formulations also include conventional sustained release
  • formulations such as tablets or granules having an enteric coating.
  • fluid unit dose forms are prepared containing the compound and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety and/or mania and/or depression and/or the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines and/or disorders treatable or preventable with anti-convulsive agents, such as epilepsy, which comprises a compound of formula (I), or a
  • the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in particular compounds of examples 1 to 50 inclusive, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety and/or mania and/or depression and/or the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines and/or disorders treatable or preventable with anti-convulsive agents, such as epilepsy.
  • Such compositions may be prepared in the manner as hereinbefore described.
  • the invention also provides novel compounds of formula (I) and
  • Examples of compounds of formula (la) include: trans-6-Cyano-3,4-dihydro-2,2-dimethyl-4-(3-fluorobenzoylamino)2H-1-benzopyran-3-ol (Example 1), trans-6-Cyano-3,4-dihydro-2,2-dimethyl-4-(2-fluoro benzoylamino)2H-1-benzopyran-3-ol (Example 2), trans-6-Trifluoromethoxy-3,4-dihvdro-2,2-dimethyl-4-(3- fluorobenzoylamino)2H-1-benzopyran-3-ol (Example 3), trans-6-Cyano-4S-(3-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1- benzopyran-3R-ol (Example 21), trans-6-Cyano-4R-(3-fluorobenzoylamino)-3,4
  • the invention further provides novel compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Y is CR 1 where R 1 and R 2 are both hydrogen or one of R 1 and R 2 is trifluoromethoxy, C 1-6 alkyl optionally interrupted with oxygen or substituted with hydroxy, C 1-6 alkoxy or substituted amino-carbonyl, CF 3 A-(where A is -CF 2 -, -CO-, - CH 2 ) or CH(OH)), aryl sulphonyl, aryl C 3-8 cycloalkyl, C 1-6 alkoxy, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulphinyl,
  • heteroarylsulphinyl heteroarylsulphonyl, in which any aromatic moiety is optionally substituted and the other is hydrogen.
  • Such compounds will hereinafter be referred to as compounds of formula (lb).
  • Examples of compounds of formula (lb) include: trans-6-Trifluoromethoxy-3,4-dihydro-2,2-dimethyl-4-(3- fluorobenzoylamino)2H-1-benzopyran-3-ol (Example 3), trans-3,4-Dihydro-2,2-dimethyl-4-(4-fluorobenzoylamino)- 2H-1-benzopyran-3-ol (Example 4), trans-4-(4-Fluorobenzoylamino)-3,4-dihydro-2,2.6-trimethyl-2H-1- benzopyran-3-ol (Example 14), trans-6-Ethyl-4-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1- benzopyran-3-ol (Example 15), trans-6-Ethyl-4-(4-fluorobenzoylethylamino)-3,4-dihydro-2,4-di
  • the present invention also provides novel compounds of formula (I) and pharmaceutically acceptable salts thereof, where Y is N and R 2 is hydrogen. Such compounds will hereinafter be referred to as compounds of formula (Ic).
  • Examples of compounds of formula (Ic) include: trans-4-(2-Fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-pyrano[3,2- c]pyridin-3-ol (Example 38), trans-4-(3-Fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-pyrano[3,2- c]pyridin-3-ol (Example 39) and trans-4-(4-Fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-pyrano[3,2- c]pyridin-3-ol (Example 40).
  • the present invention also provides novel compounds of formula (I) and pharmaceutically acceptable salts thereof, where X is NRJQ where R ⁇ is hydrogen or C 1-6 alkyl. Such compounds will hereinafter be referred to as compounds of formula (Id).
  • compounds of formula (I) may be prepared by procedures generally described or analogous to those described in EP-0126311, EP- 0376524, EP-205292, EP-0250077, EP-0093535,
  • the invention also provides a process for the preparation of novel compounds of formula (I')or pharmaceutically acceptable salts thereof, which comprises acylating a compound of formula (II'):
  • Y', R 2 ' and R 5 ' are the required variables Y, R 2 or R 5 as defined in formula (I) or a group convertible thereto and R 3 , R 4 , R 6 , R 8 , R 9 and X are the required variables as defined in formula (I), the R 8 NH group being trans to the R 5 group, with an acylating agent of formula (IIIb):
  • the present invention also provides a process for the preparation of compounds of formula (la), or a pharmaceutically
  • Y', R 2 ' and R 5 ' are Y, R 2 or R 5 as defined in formula (I) or a group convertible thereto and R 3 , R 4 , R 6 , R 8 , R 9 and X are as defined in formula (I), the R 8 NH group being trans to the R 5 ' group, with an acylating agent of formula (Ilia):
  • the present invention also provides a process for the preparation of compounds of formula (lb), or a pharmaceutically acceptable salt thereof, which comprises acylating a compound of formula (lIb):
  • R 1 ' and R 2 ' are both hydrogen or one of R 1 and R 2 is
  • the present invention also provides a process for the preparation of compounds of formula (Ic), or a pharmaceutically acceptable salt thereof, which comprises acylating a compound of formula (lie):
  • R 5 ' is R 5 , as defined in relation to formula (I) or a group convertible to R 5 and R 2 ' is hydrogen or a group convertible thereto
  • R 6 , R 3 , R 4 , R 8 , R 9 and X are as defined in formula (I), the R 8 NH group being trans to the R 5 ' group, with an acylating agent of formula (nib):
  • the present invention also provides a process for the preparation of compounds of formula (Id), or a pharmaceutically acceptable salt thereof, which comprises acylating a compound of formula (Hd):
  • X' is NR 10 ' where R 10 ' is hydrogen or C 1-6 alkyl or a group convertible thereto
  • Y', R 2 ' and R 5 are Y, R 2 and R 5 respectively as defined in formula (I) or groups convertible thereto
  • R 3 , R 4 , R 6 , R 8 and R 9 are as defined in formula (I)
  • the R 8 NH group being trans to the R 5 ' group, with an acylating agent of formula (IIIb):
  • Suitable leaving groups L 1 include those mentioned in the above-mentioned patents, in particular EP-A-0 126 311 or are
  • reaction conditions which may be used to carry out the above reactions are as outlined or analogous to those described in the abovementioned patents, in particular EP-A-0 126 311.
  • the leaving group (L 1 ) is a group that is displaceable by a primary or secondary amino nucleophile.
  • a group include C 1-4 alkylcarbonyloxy and halogen, such as chloro and bromo.
  • the acylating agent of formula (Illa) or (IIIb) is either an acid anhydride or an acid halide.
  • it is, preferably, a mixed anhydride, which may be prepared in situ from an aromatic or heteroaromatic carboxylic acid and an alkyl chlorocarbonate, such as ethyl chloroformate.
  • the acylating agent of formula (Illa) or (IIIb) is an acid anhydride
  • the acylation of the compound formula (Ila), (llb), (IIe) or (lld) is, preferably carried out using the anhydride as the solvent in the presence of an acid acceptor, such as sodium acetate.
  • the acylation of the compound of formula (IIa), (llb), (IIe) or (IId), is, preferably, carried out in a non-aqueous medium, such as methylene chloride, in the presence of an acid acceptor, such as triethylamine, trimethylamine or pyridine.
  • a non-aqueous medium such as methylene chloride
  • Suitable groups convertible to Y (or R 1 ), R 2 and R 5 include those described in the above-mentioned patents or are conventional in the art.
  • racemates for formula (I) may be resolved or enantiomerically purified compounds of formula (I) may be prepared using procedures conventional in the art and in particular using the procedures outlined in EP-0430631 and EP-0355584.
  • the procedures outlined in or analogous to those described in Example 35 of the present specification may be used to prepare specific enantiomers of any compounds of formulae (I), (I'), (la), (lb), (Ic) or (Id).
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I'), (la), (lb), (Ic) or (d), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the invention also provides the use of a compound of formula (I'), (la), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof, in the treatment and/or prophylaxis of anxiety and/or mania and/or depression and/or the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines and/or disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy.
  • Example 10 trans-6-Ethylcarbonyl-3,4-dihydro-2,2-dimethyl- 4-(4-fluorobenzoylmethylamino)2H-1-benzopyran-3-ol, Mpt. 210-212°C.
  • Example 11 trans-6- Acetyl-4-(4-fluorobenzoylmethylamino)-3,4-dihydro-2,2-dimethyl- 2H-1-benzopyran-3-ol,
  • Rats are trained on a variable interval 30 sec schedule (VI30) to press a lever in order to obtain food reward.
  • the 5 min sessions of the VI30 schedule alternate with 2-5 min of a schedule (FR5) in which every 5th lever press is followed by presentation of a food pellet paired with a 0.5 sec mild footshock.
  • the total study lasts approximately 30 mins. Rats typically respond with high rates of lever pressing under the VI30 schedule and low response rates under the FR5 'conflict' session.
  • Anxiolytic drugs increase the suppressed response rates of rats in a 'conflict' session.
  • Drugs are administered intraperitoneally or orally to groups of 3-8 rats 30 to 60 mins before testing.
  • results are expressed as the percentage increase in the square root of the total number of lever presses in the FR5 'conflict' session.
  • Square root transformation is necessary to normalise the data for statistical analysis using parametric methods.
  • the compound of Example 4 showed a significant increase in responding in the 'conflict' session at a dose of 10mg/kg p.o.
  • the maximal electroshock seizure (MES) test in rodents is one of the most widely used models of human grand mal epilepsy 1 .
  • anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.
  • mice Male, Charles River, U.K. CD-1 strain, 25-30g are randomly assigned to groups of 10-20 and dosed orally or intraperitoneally at a dose volume of 10ml/kg with various doses of compound (1-100 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a variable voltage electroshock (0.1 sec, 50 Hz, sine wave form) via a buccal and a subcutaneous electrode.
  • a variable voltage electroshock 0.1 sec, 50 Hz, sine wave form
  • the CV50 is usually 40 - 50V.
  • the first animal in the control group is subjected to a voltage of 45V. If a tonic seizure does not ensue, the voltage is increased for a subsequent mouse. If a tonic convulsion does occur, then the voltage is decreased, and so on until all the animals in the group have been tested.
  • the percentage increase or decrease in CV50 for each group compared to the control is calculated.
  • the X-maze test of anxiety examines the exploratory response of naive rats in an environment which offers both anxiogenic (open arms) and relatively non-anxiogenic (closed arms) areas. A selective increase in exploration of the open arms following drug pretreatment is therefore postulated to indicate anxiolytic effects.
  • the X-maze was raised 70cm above the floor and consisted of two enclosed arms 45cm (long) x 15cm (wide) x 10cm (high) and two open arms 45 x 10 x 1cm arranged such that the two arms of each type were opposite each other. Both arm types were marked into two equal sections. Rats were placed onto the centre of the X-maze and observed for a period of 10 minutes during which time the following parameters were recorded: 1) the number of entries onto, and the time spent on, (a) open arms, (b) closed arms, (c) end of open arms and (d) end of closed arms. 2) the number of sections crossed.
  • the fear-drive evoked in the open arms exceeds that in the enclosed arms and rats typically show a clear preference for the enclosed arms.
  • Anxiolytic drugs increase the number of entries made onto, and the time spent on, the outer half of the open arms, and also the percentage of entries made onto, and the time spent on, the whole of the open arms.
  • Drugs are administered intraperitoneally or orally to groups of 6 to 12 rats 30 to 60 mins before testing. Statistical comparisons between vehicle- and drug-treated groups were made using a Mann- Whitney 'U' test (two tailed).
  • the compound of Example 21 caused a significant increase in open arm entries at a dose of 30 mg/kg p.o.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement et/ou de prophylaxie de l'anxiété et/ou de la manie, de la dépression, des effets associés à la privation de substances toxiques, de troubles pouvant être traités et/ou empêchés à l'aide d'anticonvulsifs. Ledit procédé consiste à administrer au patient à traiter une dose efficace ou prophylactique d'un composé représenté par la formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci.
PCT/GB1992/002222 1992-11-30 1992-11-30 Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation Ceased WO1994012173A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SK709-95A SK281507B6 (sk) 1992-11-30 1992-11-30 Použitie benzopyránových analógov, benzopyránové analógy, spôsob ich prípravy a farmaceutický prostriedok s ich obsahom
PL92309219A PL173268B1 (pl) 1992-11-30 1992-11-30 Sposób wytwarzania enancjomeru trans-6-acetylo-4S-(4-fluorobenzoiloamino)- 3,4-dihydro-2,2-dimetylo-2H-1-benzopiran-3R-olu
CZ951390A CZ282172B6 (cs) 1992-11-30 1992-11-30 Benzpyranové analogy pro léčení úzkosti, mánie, deprese nebo symptomů po přerušení podávání drog nebo léčiv, způsob přípravy těchto sloučenin, jejich použití a farmaceutický prostředek obsahující tyto sloučeniny
FI952609A FI952609L (fi) 1992-11-30 1992-11-30 Bentsopyronianalogit ahdistuksen, manian, masennuksen tai vieroitusoireiden hoitamiseksi
BR9207178A BR9207178A (pt) 1992-11-30 1992-11-30 Análogos de benzopiron para tratamento de sintomas de ansiedade mania depressão ou recolhimento
HU9501563A HUT72589A (en) 1992-11-30 1992-11-30 Benzopyron analogues for the treatment of anxiety, mania, depression or withdrawal symptoms
PCT/GB1992/002222 WO1994012173A1 (fr) 1992-11-30 1992-11-30 Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation
NO19952119A NO315733B1 (no) 1992-11-30 1995-05-29 Benzopyron-analoger, deres anvendelse og farmasöytiske preparater inneholdende dem

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1992/002222 WO1994012173A1 (fr) 1992-11-30 1992-11-30 Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation

Publications (1)

Publication Number Publication Date
WO1994012173A1 true WO1994012173A1 (fr) 1994-06-09

Family

ID=10709714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/002222 Ceased WO1994012173A1 (fr) 1992-11-30 1992-11-30 Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation

Country Status (5)

Country Link
CZ (1) CZ282172B6 (fr)
FI (1) FI952609L (fr)
NO (1) NO315733B1 (fr)
SK (1) SK281507B6 (fr)
WO (1) WO1994012173A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574049A (en) * 1994-07-22 1996-11-12 Sandoz Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2H-1-benzopyrans
US6298535B1 (en) 2000-02-16 2001-10-09 William Ross Lower Wheel lifting rod assembly
JP2007516235A (ja) * 2003-10-17 2007-06-21 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング アミドメチル置換２−（４−スルホニルアミノ）−３−ヒドロキシ−３，４−ジヒドロ−２ｈ−クロメン−６−イル誘導体、該誘導体を製造するための方法及び中間生成物並びにこれらの化合物を含有する医薬品
US7576094B2 (en) 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126311A2 (fr) * 1983-05-18 1984-11-28 Beecham Group Plc Dérivés de benzopyrane.
EP0194884A1 (fr) * 1985-03-15 1986-09-17 Eli Lilly And Company Agents anticonvulseurs
EP0222996A2 (fr) * 1985-09-03 1987-05-27 Ciba-Geigy Ag 3-Amino-dihydro(1)benzopyranne et benzothiopyranne
EP0339562A1 (fr) * 1988-04-26 1989-11-02 Yoshitomi Pharmaceutical Industries, Ltd. Composé benzopyranique et son usage pharmaceutique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126311A2 (fr) * 1983-05-18 1984-11-28 Beecham Group Plc Dérivés de benzopyrane.
EP0194884A1 (fr) * 1985-03-15 1986-09-17 Eli Lilly And Company Agents anticonvulseurs
EP0222996A2 (fr) * 1985-09-03 1987-05-27 Ciba-Geigy Ag 3-Amino-dihydro(1)benzopyranne et benzothiopyranne
EP0339562A1 (fr) * 1988-04-26 1989-11-02 Yoshitomi Pharmaceutical Industries, Ltd. Composé benzopyranique et son usage pharmaceutique

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574049A (en) * 1994-07-22 1996-11-12 Sandoz Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2H-1-benzopyrans
US6298535B1 (en) 2000-02-16 2001-10-09 William Ross Lower Wheel lifting rod assembly
JP2007516235A (ja) * 2003-10-17 2007-06-21 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング アミドメチル置換２−（４−スルホニルアミノ）−３−ヒドロキシ−３，４−ジヒドロ−２ｈ−クロメン−６−イル誘導体、該誘導体を製造するための方法及び中間生成物並びにこれらの化合物を含有する医薬品
JP4791968B2 (ja) * 2003-10-17 2011-10-12 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング アミドメチル置換２−（４−スルホニルアミノ）−３−ヒドロキシ−３，４−ジヒドロ−２ｈ−クロメン−６−イル誘導体、該誘導体を製造するための方法及び中間生成物並びにこれらの化合物を含有する医薬品
US7576094B2 (en) 2004-12-13 2009-08-18 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors

Also Published As

Publication number Publication date
FI952609A0 (fi) 1995-05-29
NO952119D0 (no) 1995-05-29
NO952119L (no) 1995-05-29
FI952609A7 (fi) 1995-05-30
SK70995A3 (en) 1995-11-08
FI952609L (fi) 1995-05-30
NO315733B1 (no) 2003-10-20
SK281507B6 (sk) 2001-04-09
CZ139095A3 (en) 1996-01-17
CZ282172B6 (cs) 1997-05-14

Similar Documents

Publication Publication Date Title
EP0587645B1 (fr) Derives de benzo- et pyridopyrane presentant une activite anxiolytique et anticonvulsive
EP0901482A1 (fr) Carboxamides de benzofurane et leurs utilisations therapeutiques
US5861394A (en) Use of N-substituted phenothiazines
AU679955B2 (en) Pharmaceutical composition containing bicyclic type compounds
US5624954A (en) Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity
WO1994012173A1 (fr) Analogues de benzopyrone pour le traitement de l'anxiete, de la manie, de la depression ou des symptomes de privation
AU679475B2 (en) Bicyclic compounds with pharmaceutical activity
EP0673248A1 (fr) Activateurs des vannes a potassium utilises en therapie
WO1995034547A1 (fr) Composes a substitution amide c-4 et leur utilisation en tant qu'agents therapeutiques
EP1091950A1 (fr) Derives de benzopyrane substitue et leur utilisation comme agents anti-convulsifs
AP360A (en) Benzo-and pyridopyran derivatives having anxiolytic and anticonvulsant activity.
EP0764158B1 (fr) Benzopyrannes et leur utilisation en tant qu'agents therapeutiques
HK1039613A (en) Trans-6-acetyl-4s-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2h-1-benzopyran-3r-ol
HK1019004B (en) Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity
SI9200378A (en) Benzopyran derivates and heterocyclic analogs thereof as pharmacologically active agents
EP0322251A2 (fr) Dérivés de benzothiopyrane
US20010021780A1 (en) Pharmaceutical composition containing bicyclic type compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR BY CS FI HU KZ NO PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 70995

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 952609

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: PV1995-1390

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: PV1995-1390

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1995-1390

Country of ref document: CZ